FDA Approves Lorbrena (lorlatinib) for Previously-Treated ALK-Positive Metastatic Non-Small Cell Lung Cancer

Article Link: FDA Approves Lorbrena (lorlatinib) for Previously-Treated ALK-Positive Metastatic Non-Small Cell Lung Cancer

November 2, 2018 Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug
Administration (FDA) has approved Lorbrena [lor-BREN-ah] (lorlatinib),
a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase
inhibitor (TKI) for…

Source: FDA New Drug Approvals